

La investigación extendida: la eficacia e impulso de trabajar en red aquí i allá



Josep Samitier Vicerector d'Innovació i Programes Internacionals de Recerca

Una historia con final abierto

INVESTIGACIÓN EXTENDIDA

- Inter-relación entre diferentes agentes públicos y privados. De la red a la malla.
- Cooperación local y global: masas críticas
- Estrategias coordinadas autonómicas, estatales y europeas
- Múltiples instrumentos: estructuras flexibles
- Beneficios que deben percibirse para todos

Nanomedicine


Nanotechnology for Health

European Technology Platform

Strategic Research Agenda for Nanomedicine




October 2008



Definition: NanoMedicine, for the purpose of this vision document, is defined as the application of Nanotechnology to Health. It exploits the improved and often novel physical, chemical, and biological properties of materials at the nanometric scale. NanoMedicine has potential impact on the prevention, early and reliable diagnosis and treatment of diseases.

108 members

Observers: Industry, Education and Science, and Health Ministries.
Regional Governments



Hospitals:

Public hospitals

Technology Centres:

Centres to promote and facilitate technological innovation and development processes

Research Centres: Universities
Spanish National Research Council
Research Institutes
Scientific Parks

Participants from Industry

Pharma

ActiVery
ACTIVE DRUG DELIVERY

**neuro
pharma**

ITALFARMACO SA

MERCK

NOVARTIS

**Pharma
Mar**

ellerix

**KERN
PHARMA**

Other

Bexen

Medical products

**Atos
Origin**

IT services provider

SENER

Engineering company

Biotech

ADVANCELL

Cell-based products

Biomedal

Postgenomics research

dendrico

Dendrimers

INGENIATRICS

Microfluidic solutions

GMW Associates Magnetic sensors

**Oryzon
genomics**

Functional genomics company

PROGENIKA

Functional genomics company

Sentia

Multibiosensor systems

Biobide S.L.

Screening

NANOGAP
SUBSTITUTED POWDERS

Nanoparticles

Oral implants

Oral implants

HIPRA

Diagnostics

**ENDO
R**

Nanomedicine

PRESENTACIÓN DEL INFORME

Impulsar la colaboración

Participar en iniciativas internacionales

Establecer recomendaciones

Comunicación y Disseminación



3 programas :

- ❖ Ministerio de Educación y Ciencia: CONSOLIDER
- ❖ Ministerio de Industria: CENIT
- ❖ Ministerio de Sanidad: CIBER



The logo for Ciber-66n, with "ciber" in blue and "66n" in red, both in a stylized, italicized font.

Consortium:

29 Spanish groups from
public hospitals, universities
and research centres
January 2007.

Activities:


3 main research areas:

- Nanomedicine
- Biomaterials and Regenerative Medicine
- Bioengineering and Medical Images

Consortium :



ONCnosis Pharma A.I.E.



CONSORTIUM

- 7 Companies
- 20 Collaborators:
 - ✓ 11 Universities
 - ✓ 6 Research centres
 - ✓ 1 Science Park
 - ✓ 1 Hospital
 - ✓ 1 Foundation





MADRID BIOCLUSTER



Red de Parques y Clusters de la Comunidad de Madrid
Madrid Region Parks & Clusters Network

MADRID
BIOCLUSTER




Conferencia Anual de las Plataformas Tecnológicas de Investigación Biomedicina: Medicamentos Innovadores y Nanomedicina

Barcelona, 26-27 de Noviembre de 2007

Dos apuestas estratégicas del Gobierno Vasco

Un interés común




INDUSTRIA



SANIDAD

▶ Qué es Biocat ?

Biocat es la organización, impulsada por la Generalitat y formada por empresas privadas e instituciones públicas de investigación, que dinamiza el sector biotecnológico y biomédico en Catalunya






Research Institutes




Core Facilities



Private Companies



BioPol L'H



Parc Científic de la Salut de l'Hospitalet

Parc Empresarial L'H

Campus Universitari de la Salut de la Universitat de Barcelona:

Facultats de Medicina i Odontologia
Escola d'Infermeria i Podologia. Clíniques Odontològica i Podològica

Hospital Universitari de Bellvitge (ICS)

Hospital Duran i Reynalds (Institut Català d'Oncologia).

Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)

Institut de Bioenginyeria de Catalunya (IBEC).

300.000m² dedicados a las ciencias de la salud



Institut de bioenginyeria de Catalunya

OBJECTIVES

- Basic and interdisciplinary research at highest international level
- Knowledge and technology transfer in Bioengineering, as well as innovation. Collaboration with industry and hospitals.
- Creation of spin-off companies
- Training in Bioengineering



Created by the end of 2005






**NANOTECNOLOGIA
Y NANOMEDICINA
EN BARCELONA**

Barcelona Alliance for Nanotechnology and Nanomedicine



NANOTECNOLOGIA
Y NANOMEDICINA
EN BARCELONA

Nanomedicine Cluster



“The university thus comprises a powerful creative hub in regional development”

The university and the creative economy

Richard Florida et al. 2006.